603 related articles for article (PubMed ID: 17621865)
21. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
Sulkes A
Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
[TBL] [Abstract][Full Text] [Related]
22. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
Freedman GM; Anderson P; Li T; Ross E; Swaby R; Goldstein L
Cancer; 2006 Dec; 107(11):2552-8. PubMed ID: 17061250
[TBL] [Abstract][Full Text] [Related]
23. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
[TBL] [Abstract][Full Text] [Related]
25. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Barginear M; Clotfelter A; Poznak CV
Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
[TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
27. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Aapro M
Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
[TBL] [Abstract][Full Text] [Related]
28. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
29. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Ghazi M; Roux C
Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
31. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
Monnier A
Cancer Treat Rev; 2006 Nov; 32(7):532-40. PubMed ID: 16978789
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
34. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
35. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Hadji P
Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer adjuvant endocrine therapy.
Cigler T; Goss PE
Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
[TBL] [Abstract][Full Text] [Related]
38. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
39. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
40. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
